SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 35 filers reported holding SEELOS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $206,000 | -73.8% | 200,135 | -82.7% | 0.00% | -100.0% |
| Q2 2022 | $785,000 | -45.4% | 1,154,419 | -32.8% | 0.00% | -50.0% |
| Q1 2022 | $1,438,000 | +277.4% | 1,716,755 | +984.6% | 0.00% | – |
| Q3 2021 | $381,000 | -67.5% | 158,278 | -64.3% | 0.00% | -100.0% |
| Q2 2021 | $1,171,000 | +5.5% | 443,500 | -36.9% | 0.00% | 0.0% |
| Q4 2020 | $1,110,000 | +100.4% | 702,486 | +18.8% | 0.00% | 0.0% |
| Q3 2020 | $554,000 | -44.0% | 591,086 | -39.7% | 0.00% | 0.0% |
| Q2 2020 | $989,000 | +87.0% | 979,586 | -9.2% | 0.00% | 0.0% |
| Q1 2020 | $529,000 | -64.7% | 1,078,379 | -3.6% | 0.00% | 0.0% |
| Q4 2019 | $1,499,000 | +61.7% | 1,118,623 | +10.8% | 0.00% | 0.0% |
| Q3 2019 | $927,000 | -54.5% | 1,009,958 | +8.7% | 0.00% | -50.0% |
| Q2 2019 | $2,036,000 | +27.1% | 929,465 | +95.0% | 0.00% | +100.0% |
| Q1 2019 | $1,602,000 | – | 476,765 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500,000 | $4,075,000 | 1.71% |
| Connacht Asset Management LP | 498,925 | $813,000 | 0.79% |
| GENDELL JEFFREY L | 2,449,267 | $3,992,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 2,133,436 | $3,478,000 | 0.21% |
| Uniplan Investment Counsel, Inc. | 1,550,359 | $2,527,000 | 0.14% |
| Financial Advocates Investment Management | 24,673 | $1,994,000 | 0.13% |
| Connacht Asset Management LP | 72,300 | $118,000 | 0.12% |
| Woodline Partners LP | 4,047,231 | $6,597,000 | 0.09% |
| 1492 Capital Management LLC | 108,286 | $177,000 | 0.09% |
| Ikarian Capital, LLC | 244,171 | $398,000 | 0.06% |